NEWSROOM
News & Stories
Newsroom
Press Releases
Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion
Agendia and Roche evaluate BluePrint’s stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 10, 2020 – Agendia, Inc., a world leader in precision oncology Read More
Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020
Agendia shares subgroup analyses from the first of its kind, national FLEX Registry with complete, clinically-annotated full genome expression profiling IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., a world Read More
FOCUS Study Shows MammaPrint Accurately Identifies Extremely Indolent Cancers
Findings confirm subanalysis of STO-3 trial and provide foundation for consideration of de-escalation of treatment in post-menopausal patients guided by genomic testing IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2020 – Agendia, Inc., Read More